Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jakub, Żołnierek"'
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Magdalena Wieczorek-Rutkowska, Anna Kopczyńska, Lubomir Bodnar, Jakub Żołnierek, Pawel Chrom, Piotr Tomczak
Publikováno v:
Clinical Genitourinary Cancer. 17:e556-e564
Background Cabozantinib is an approved treatment for metastatic renal cell carcinoma (mRCC). This report presents an analysis of the safety profile and efficacy of cabozantinib in an unselected population from Poland. Patients and Methods Patients wi
Autor:
Anna Waśko-Grabowska, Grzegorz Opolski, Sebastian Szmit, Jakub Żołnierek, Paweł Nurzyński, Magdalena Zaborowska, Krzysztof J. Filipiak, Cezary Szczylik
Publikováno v:
Kidneyblood pressure research. 35(6)
Background/Aims: The purpose of the present study was to determine the relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib.
Autor:
Cezary Szczylik, Anna Waśko-Grabowska, Jakub Żołnierek, Beata Obrocka, Paweł Nurzyński, Sylwia Oborska, Ewa Kuszatal, Przemysław Langiewicz
Publikováno v:
Scopus-Elsevier
Introduction This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone l